Alnylam Pharmaceuticals Inc. faces a notable decline in stock value as concerns about its recent initiatives and market performance surface.
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) experienced a significant drop in its stock price today, closing down 3.07% at CA$239.18. This decline raises questions about the company's future prospects amidst a competitive landscape in RNA therapeutics.
Investor takeaway: Investors should closely monitor Alnylam's ongoing initiatives and market positioning, as today's drop could indicate underlying challenges that may affect long-term growth.
Advertisement
Alnylam Pharmaceuticals Inc
ALNY.US
ALNY.US
Alnylam Pharmaceuticals Inc
WealthAwesomeMarket cap
$34.00B
P/E
44.4x
52W high
$495.55
52W low
$197.81
1W change
+0.09%
Beta
0.30
Analyst Price Targets
Based on 30 analysts covering ALNY · as of Sep 17, 2026
Wall Street analysts forecast ALNY stock price to rise 50.5% over the next 12 months.
Consensus
Buy4.23 / 5.00
Avg. Target
C$371.35
+50.5% Upside
Current Price
C$246.74
Last close
Analyst Breakdown (30 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ALNY's historical volatility
30-Day Vol
46.5%
Annualized
90-Day Vol
76.1%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$206.39
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$232.48 | C$198.02 – C$272.94 |
| 60 trading days | C$219.05 | C$174.58 – C$274.84 |
| 90 trading days | C$206.39 | C$156.31 – C$272.51 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Bull case
Alnylam's innovative RNAi therapeutics, including AMVUTTRA, show strong commercial potential. The company has seen significant revenue growth, driven by increased patient demand for its treatments.
Bear case
The recent stock decline may reflect investor skepticism about Alnylam's ability to maintain its market position. Increasing competition and challenges in patient awareness and diagnosis of conditions treated by its products could pose risks to its growth trajectory.
Market Reaction
Alnylam's stock price fell sharply today, reflecting a broader market sentiment that may be questioning the sustainability of its growth. Despite recent initiatives to raise awareness about its treatments, investor confidence appears shaken, leading to the notable decline.
Advertisement
Recent Initiatives and Challenges
The launch of the 'Play by Play' initiative, aimed at educating patients about ATTR-CM, highlights Alnylam's commitment to improving patient outcomes. However, the effectiveness of such campaigns in driving awareness and sales remains uncertain, especially in a competitive market where other RNA therapeutics are gaining traction.
Looking Ahead
As Alnylam navigates these challenges, investors will need to keep a close eye on upcoming clinical data and market strategies. The company's ability to sustain its revenue growth and maintain a competitive edge will be crucial in determining its stock performance in the coming months.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
